Even difficult-to-formulate active ingredients can be manufactured into core tablets: OSDrC technology and contract formulation development.
Introducing the nucleation of poorly formed nuclei! It is possible to encapsulate the inner drug in powder form within the outer layer.
The "OSDrC" technology allows for precise and flexible control of the inner core due to its variable double-structure pestle, enabling the production of higher quality core tablets than ever before, as well as the development of various new dosage forms. The "OSDrC" does not require a supply process for the inner core, allowing even difficult-to-form powders to be included in the inner core. In other words, it is possible to encapsulate the inner core drug in powder form with the outer layer, making it applicable to orally disintegrating tablets. If pellets are placed in the inner core, it is also possible to convert capsule formulations into tablet forms. In this way, it can significantly change the traditional formulation design process. 【Features】 ■ Does not require a supply process for the inner core ■ Can include difficult-to-form powders in the inner core ■ If pellets are placed in the inner core, it is possible to convert capsule formulations into tablets *For more details about OSDrC technology, please refer to the OSDrC main brochure on the special website below or feel free to contact us.
Inquire About This Product
basic information
Please feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
Please feel free to contact us.
catalog（2）
Download All Catalogs
Company information
Sanwa Chemical Research Institute, as a member of the Suzuken Group focused on health creation, provides services aimed at improving the quality of life (QOL) for people who wish for better health, centered around its two main businesses: "pharmaceuticals" and "diagnostic drugs." In the "pharmaceuticals business," we are steadily building a track record with a focus on new drugs in the areas of diabetes and kidney/dialysis-related fields. In the "diagnostic drugs business," we are continuously developing and launching self-blood glucose meters, sensors, and diagnostic drugs for infectious diseases. Furthermore, by adding two more businesses— the "OSDrC (Osudrack) business" utilizing innovative formulation technology and the "contract manufacturing business" with advanced quality control systems— Sanwa Chemical Research Institute continues to evolve further.
